OSE Immunotherapeutics SA (6OP) Stock Statistics & Valuation Metrics
Total Valuation
OSE Immunotherapeutics SA has a market cap or net worth of EUR 45.93M. The enterprise value is EUR 128.21M.
- Market Cap
- EUR 45.93M
- Enterprise Value
- EUR 128.21M
Share Statistics
OSE Immunotherapeutics SA has 23,560,110 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 23,560,110
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
OSE Immunotherapeutics SA’s return on equity (ROE) is -1.38 and return on invested capital (ROIC) is -67.00%.
- Return on Equity (ROE)
- -1.38
- Return on Assets (ROA)
- -0.48
- Return on Invested Capital (ROIC)
- -67.00%
- Return on Capital Employed (ROCE)
- -0.90
- Revenue Per Employee
- 40.92K
- Profits Per Employee
- -589.06K
- Employee Count
- 64
- Asset Turnover
- 0.03
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of OSE Immunotherapeutics SA is -1.09. OSE Immunotherapeutics SA’s PEG ratio is 0.01.
- PE Ratio
- -1.09
- PS Ratio
- 16.61
- PB Ratio
- 1.52
- Price to FCF
- -1.27
- Price to Operating Cash Flow
- -1.22
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, OSE Immunotherapeutics SA had revenue of 2.62M and earned -37.70M in profits. Earnings per share was -1.69.
- Revenue
- 2.62M
- Gross Profit
- 2.62M
- Operating Income
- -48.06M
- Pretax Income
- -42.05M
- Net Income
- -37.70M
- EBITDA
- -44.81M
- Earnings Per Share (EPS)
- -1.69
Cash Flow
In the last 12 months, operating cash flow was -34.03M and capital expenditures -97,999, giving a free cash flow of -34.13M billion.
- Operating Cash Flow
- -34.03M
- Free Cash Flow
- -34.13M
- Free Cash Flow per Share
- -1.52
Dividends & Yields
OSE Immunotherapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -78.44%
- Earnings Yield
- -90.83%
Stock Price Statistics
- Beta
- 0.90
- 52-Week Price Change
- -64.00%
- 50-Day Moving Average
- 2.48
- 200-Day Moving Average
- 3.43
- Relative Strength Index (RSI)
- 45.37
- Average Volume (3m)
- 1,200
Important Dates
OSE Immunotherapeutics SA upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 28, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
OSE Immunotherapeutics SA as a current ratio of 1.28, with Debt / Equity ratio of 129.37%
- Current Ratio
- 1.28
- Quick Ratio
- 1.28
- Debt to Market Cap
- 0.28
- Net Debt to EBITDA
- -0.40
- Interest Coverage Ratio
- -16.26
Taxes
In the past 12 months, OSE Immunotherapeutics SA has paid -4.37M in taxes.
- Income Tax
- -4.37M
- Effective Tax Rate
- 0.10
Enterprise Valuation
OSE Immunotherapeutics SA EV to EBITDA ratio is -1.62, with an EV/FCF ratio of -1.80.
- EV to Sales
- 23.42
- EV to EBITDA
- -1.62
- EV to Free Cash Flow
- -1.80
- EV to Operating Cash Flow
- -1.80
Balance Sheet
OSE Immunotherapeutics SA has EUR 22.65M in cash and marketable securities with EUR 35.38M in debt, giving a net cash position of -EUR 12.73M billion.
- Cash & Marketable Securities
- EUR 22.65M
- Total Debt
- EUR 35.38M
- Net Cash
- -EUR 12.73M
- Net Cash Per Share
- -EUR 0.54
- Tangible Book Value Per Share
- -EUR 0.63
Margins
Gross margin is 0.00%, with operating margin of -1835.01%, and net profit margin of -1439.48%.
- Gross Margin
- 0.00%
- Operating Margin
- -1835.01%
- Pretax Margin
- -1605.73%
- Net Profit Margin
- -1439.48%
- EBITDA Margin
- -1442.65%
- EBIT Margin
- -1567.43%
Analyst Forecast
The average price target for OSE Immunotherapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -96.25%
- EPS Growth Forecast
- -197.89%
